First time users: You will need to check your degree as you created an ACMG account. The system designates educational credits according to your degree. Be sure you are logged in (do you see your name on the top right under the ACMG Genetics Academy logo?). If not, log in before proceeding.

For technical support, please send an email to: education@acmg.net  or call 301-718-9603.

Or click on the "Help"  icon on the left-hand side of your screen for more information.

April 26, 2022 - ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series - OnDemand

Date of Release: May 5, 2022

Expiration Date: May 31, 2024

Credits offered: CME

Estimate time of completion: 1 hour

Course must be completed by the expiration date

Course Description:

Challenges of implementing multiomics analysis into clinical care – case vignettes from the molecular tumor board at NCT Heidelberg.

Target Audience:

All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic and VICC consortia, and ACMG.

Learning Objectives:

At the conclusion of this session, participants should be able to:

1. Describe how to approach complex molecular datasets for clinical curation.
2. Discuss the omics data in a molecular tumor board
3. Evaluate the clinical significance of multiomics analysis

Moderator:

Manuela Benary, PhD

Bioinformatician

Charité – Universitätsmedizin Berlin, Berlin, Germany

Presenter(s):

Peter Horak, MD, PhD

Medical Oncologist for Clinical Translation

National Center for Tumor Diseases, Heidelberg, Germany

I serve as the Deputy Head of the Department of Translational Medical Oncology at NCT Heidelberg and the German Cancer Research Center (DKFZ). Following my training in internal medicine, hematology, and medical oncology at the Medical University of Vienna, I did postdoctoral research at the Massachusetts General Hospital Cancer Center and Harvard Medical School. After several years practicing clinical oncology, I joined the Department of Translational Medical Oncology in 2016 to focus on the clinical impact of comprehensive molecular and functional characterization of individual tumors in the NCT/DKTK MASTER program. I am primarily interested the discovery, development and standardization of novel biomarkers from large molecular datasets and their translation into the medical decision-making process. During the last years, we established a clinical workflow of precision oncology for rare cancer patients, demonstrating the clinical benefit of a molecularly-stratified therapeutic approach. With regard to standardization efforts in precision oncology, I participate in national and international consortia concentrating on development of guidelines for translation of biomarker-stratified precision medicine to routine clinical care. My research projects include retrospective analyses of –omic and clinical outcome data for discovery of predictive biomarkers/signatures as well as the development of T-cell-based immunotherapies in specific subtypes of soft-tissue sarcomas. I have an ongoing interest in the clinical implementation and impact evaluation of novel methodologies in precision oncology workflows, including predictive immunotherapy signatures, proteomic and epigenetic datasets.

Veronica Teleanu, MD

Medical Oncologist Clinical Translation

National Center for Tumor Diseases, Heidelberg, Germany

 
I am a medical oncologist at the National Center for Tumor Diseases in Heidelberg where I joined the Translational Medical Oncology Team in 2019. My areas of interest are Molecular Tumor Boards and ultra-rare sarcomas where I care for patients in the outpatient clinic of the Sarcoma Service. Together with my colleagues, I am involved in several projects focusing on identification of molecular biomarkers in rare cancers using a multi-omics approach within the frame of the NCT/DKTK MASTER program and improving interpretation of molecular data for targeted therapies recommendations.

I received my MD from the University of Cluj-Napoca in Romania and subsequently completed my training in hematology/oncology in Bucharest (RO) and at the University of Ulm in Germany, were I additionally gained expertise in cytogenetics of myeloid malignancies and served as deputy of the Cytogenetics Lab of the department.

Planning Committee:

Beth Pitel, MS, CG(ASCP)
Gordana Raca, MD, PhD, FACMG
Manuela Benary, PhD
Jason Saliba, PhD
Jane Radford, MHA, CHCP  

Continuing Medical Education (CME AMA & CME Other)

Accreditation

The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American College of Medical Genetics and Genomics designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Claiming your Educational Credits

This activity consists of: View content, take a post-test, the test may be taken as often as necessary to achieve a passing score of 80% or better is required to receive credit.  If you do not achieve a passing score, the program will identify which questions you answered incorrectly so that you can review the module and try again. Complete the evaluation form.

Accredited Continuing Education Financial Disclosure

The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.

ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all relevant financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.
*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

ACMG Education Policies

Please review the policies below regarding the ACMG Education program

• Financial Disclosures and Mitigation Procedure
• ACMG Content Validation Policy
• ACMG Content Branding Policy

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclaimer

ACMG educational programs are designed primarily as an educational tool for health care providers who wish to increase their understanding of the application of genomic technologies to patient care. The ACMG does not endorse or recommend the use of this educational program to make patient diagnoses, particular by individuals not trained in medical genetics. Adherence to the information provided in these programs does not necessarily ensure a successful diagnostic outcome. The program should not be considered inclusive of all proper procedures and or exclusive of other procedures and that are reasonably directed at obtaining the same results. In determining the propriety of any specific procedure or, a healthcare provider should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen.